Lv4
430 积分 2022-05-17 加入
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
5小时前
待确认
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
5小时前
已完结
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
6小时前
已完结
Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group
2个月前
已完结
Ultra-low-dose radiation for gastric MALT lymphoma
2个月前
已完结
Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma
2个月前
已关闭
Marginal-Zone Lymphomas
2个月前
已完结
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
4个月前
已完结
Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma
4个月前
已完结
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
